Mental Disorders

274 trials 116 recruiting

Filter these 274 trials by phase, country and sponsor.

Open in Search →

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia Recruiting

2025-521868-35-00 Schizophrenia 4 2026-04-08
PHArmacoKinetics of methYLphenidate in adult patients with ADHD: comparison between patients with and without OBesity_PHACYLOB. Recruiting

2024-519461-22-00 Attention Deficit Disorder with or without Hyperactivit 6 2026-03-30
DT-101 in Adults with Major Depressive Disorder Recruiting

2025-522784-15-00 Major Depressive Disorder 4 2026-03-24
An Open-label Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression Recruiting

2025-524841-28-00 Major Depressive Disorder 4 2026-03-13
REDUCE: Research on sustained-release dexamphetamine treatment for cocaine use disorder Recruiting

2023-505556-21-00 cocaine use disorder 5 2026-03-12
Comparison of esketamine with an antidepressant versus aripiprazole with an antidepressant, in the refractory major depression disorder in e… Recruiting

2024-512672-34-00 Refractory major depression disorder (RMDD) 5 2026-02-20
"SAFE DISCONTINUATION OF ANTIDEPRESSANTS IN INDIVIDUALS WITH CLINICALLY REMITTED DEPRESSIVE DISORDERS" Recruiting

2023-509377-23-00 Patients with currently remitted depressive disorders. 6 2026-02-13
CombiChronoS - Effectiveness of a Combination of Chronotherapeutics for the Treatment of Major Depressive Episode (MDE) with Insomnia: A Mul… Recruiting

2024-516371-32-00 insomnia 5 2026-01-28
Psilocybin versus Personalized Neuromodulation for Resistant Depression (PSILO-MODULATION) Recruiting

2024-519844-34-03 Treatment Resistant Depression (TRD) 4 2026-01-19
A medical study testing the safety and effectiveness of BP1.4979, a new drug for adults with obsessive-compulsive disorder. Recruiting

2025-522026-13-00 Obsessive compulsive disorder 4 2026-01-12
Evaluation of NBI-1117568 in Inpatient Adults with Schizophrenia Recruiting

2025-521215-39-00 Schizophrenia 5 2025-12-08
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting

2025-520612-34-00 Agitation Associated with Alzheimer’s Disease 5 2025-11-28
A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious… Recruiting

2025-522347-18-00 Major Depressive Disorder (MDD), with or without Anxiou 4 2025-11-26
A study to assess the efficacy and safety of ITI-1284 as adjunctive treatment in patients with Generalized Anxiety Disorder Recruiting

2024-513302-56-00 Generalized Anxiety Disorder 4 2025-11-17
Assessment of microglial activation in patients with schizophrenia stratified for C4 complement by PET using [18F]DPA-714 Recruiting

2023-504181-38-00 pathology studied is schizophrenia 10 2025-11-17
A Trial to Examine the Effects of MSP-2020 on Brain Activity in Healthy Adults Recruiting

2025-522930-29-00 Incomplete Response - Major Depressive Disorder (IR-MDD 3 2025-11-17
Silexan® in mild to moderate major depressive disorder Recruiting

2025-521744-37-00 Mild to moderate major depressive disorder 5 2025-11-17
Psilocybin's effects on anhedonia Recruiting

2024-519265-22-00 Major Depressive Disorder 3 2025-11-12
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting

2024-520165-32-00 BP-I mania or mania with mixed features 5 2025-11-04
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting

2025-520613-31-00 Agitation Associated with Alzheimer’s Disease 5 2025-10-31
A Phase 3 Trial to Assess CYB003 in Major Depressive Disorder Recruiting

2024-519270-40-00 Major Depressive Disorder 5 2025-10-30
Sleeping through Menopause Recruiting

2024-512071-12-00 Insomnia 6 2025-10-29
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520747-32-00 Mild to moderate Alzheimer’s Disease 5 2025-10-29
Study to assess the maintenance of effect of NBI-1065845 as an adjunctive treatment in participants with Major Depressive Disorder (MDD) Recruiting

2025-520541-72-00 Major Depressive Disorder 5 2025-10-22